Mostrar el registro sencillo del ítem

dc.contributor.authorArafet Cruz, Kemel
dc.contributor.authorFerrer Castillo, Silvia
dc.contributor.authorMoliner, Vicent
dc.date.accessioned2016-03-22T10:18:35Z
dc.date.available2016-03-22T10:18:35Z
dc.date.issued2015-05-12
dc.identifier.citationARAFET, Kemel; FERRER, Silvia; MOLINER, Vicent. First Quantum Mechanics/Molecular Mechanics Studies of the Inhibition Mechanism of Cruzain by Peptidyl Halomethyl Ketones. Biochemistry, 2015, vol. 54, no 21, p. 3381-3391.ca_CA
dc.identifier.issn0006-2960
dc.identifier.urihttp://hdl.handle.net/10234/154786
dc.description.abstractCruzain is a primary cysteine protease expressed by the protozoan parasite Trypanosoma cruzi during Chagas disease infection, and thus, the development of inhibitors of this protein is a promising target for designing an effective therapy against the disease. In this paper, the mechanism of inhibition of cruzain by two different irreversible peptidyl halomethyl ketones (PHK) inhibitors has been studied by means of hybrid quantum mechanics/molecular mechanics−molecular dynamics (MD) simulations to obtain a complete representation of the possible free energy reaction paths. These have been traced on free energy surfaces in terms of the potential of mean force computed at AM1d/MM and DFT/MM levels of theory. An analysis of the possible reaction mechanisms of the inhibition process has been performed showing that the nucleophilic attack of an active site cysteine, Cys25, on a carbon atom of the inhibitor and the cleavage of the halogen−carbon bond take place in a single step. PClK appears to be much more favorable than PFK from a kinetic point of view. This result would be in agreement with experimental studies in other papain-like enzymes. A deeper analysis of the results suggests that the origin of the differences between PClK and PFK can be the different stabilizing interactions established between the inhibitors and the residues of the active site of the protein. Any attempt to explore the viability of the inhibition process through a stepwise mechanism involving the formation of a thiohemiketal intermediate and a three-membered sulfonium intermediate has been unsuccessful. Nevertheless, a mechanism through a protonated thiohemiketal, with participation of His159 as a proton donor, appears to be feasible despite showing higher free energy barriers. Our results suggest that PClK can be used as a starting point to develop a proper inhibitor of cruzain.ca_CA
dc.description.sponsorShipWe thank the FEDER Spanish Ministerio de Economia y ́ Competitividad for Project CTQ2012-36253-C03-01, Generalitat Valenciana for the PrometeoII/2014/022 project, and Universitat Jaume I for Project P11B2014-26. K.A. thanks the Spanish Ministerio de Economia y Competitividad for a ́ predoctoral contract.ca_CA
dc.format.extent11 p.ca_CA
dc.format.mimetypeapplication/pdfca_CA
dc.language.isoengca_CA
dc.publisherACS Publicationsca_CA
dc.relation.isPartOfBiochemistry, 2015, vol. 54, no 21ca_CA
dc.rightsCopyright © 2015 American Chemical Societyca_CA
dc.rights.urihttp://rightsstatements.org/vocab/InC/1.0/*
dc.subjectChagas diseaseca_CA
dc.subjectPHK inhibitorsca_CA
dc.subjectQM/MMca_CA
dc.subjectMolecular Dynamicsca_CA
dc.subjectPMFca_CA
dc.titleFirst Quantum Mechanics/Molecular Mechanics Studies of the Inhibition Mechanism of Cruzain by Peptidyl Halomethyl Ketonesca_CA
dc.typeinfo:eu-repo/semantics/articleca_CA
dc.identifier.doihttp://dx.doi.org/10.1021/bi501551g
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessca_CA
dc.relation.publisherVersionhttp://pubs.acs.org/doi/abs/10.1021/bi501551gca_CA
dc.type.versioninfo:eu-repo/semantics/acceptedVersionca_CA


Ficheros en el ítem

Thumbnail
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem